Bad Soden am Taunus, Germany

Klaus Hutter


Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 1992-1996

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Klaus Hutter: Innovator in Pharmaceutical Compounds

Introduction

Klaus Hutter is a notable inventor based in Bad Soden am Taunus, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with pharmacological properties. With a total of 5 patents to his name, Hutter's work has had a considerable impact on antibiotic research.

Latest Patents

Hutter's latest patents include innovative methods for producing pharmacologically active compounds. One of his notable inventions is related to Penicillium cultures capable of producing 10-membered ring lactones. This process allows for the preparation of new 10-membered ring lactones that exhibit pharmacological action. Another significant patent involves a process for the production of furans and lactones from various Streptomyces species. These compounds are known for their pharmacological, particularly antibiotic, properties.

Career Highlights

Klaus Hutter has been associated with Hoechst Aktiengesellschaft, a prominent company in the pharmaceutical sector. His work at Hoechst has allowed him to explore and develop new compounds that contribute to advancements in medicine. Hutter's research has been instrumental in the ongoing quest for effective antibiotics and other therapeutic agents.

Collaborations

Hutter has collaborated with several esteemed colleagues in his field, including Susanne Grabley and Joachim Wink. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical compounds.

Conclusion

Klaus Hutter's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an innovator in the industry. His work continues to influence the development of new therapeutic agents that can address critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…